1.15
-0.05 (-4.17%)
| Previous Close | 1.20 |
| Volume | 59,368 |
| Price / Sales | 2.60 |
| Price / Book | 1.59 |
| 52 Weeks Range |
| Profit Margin | -224.45% |
| Operating Margin (TTM) | -1,190.34% |
| Diluted EPS (TTM) | -1.32 |
| Quarterly Revenue Growth (YOY) | -71.90% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | -12.57 M |
| Levered Free Cash Flow (TTM) | -7.74 M |
| Return on Assets (TTM) | -51.17% |
| Return on Equity (TTM) | -97.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Marker Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -2.33 |
|
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.42% |
| % Held by Institutions | 36.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 554,250 |
| Aisling Capital Management Lp | 30 Jun 2026 | 325,370 |
| Concurrent Investment Advisors, Llc | 30 Jun 2026 | 67,963 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |